Search

Your search keyword '"Hashine, Katsuyoshi"' showing total 324 results
Start Over Author "Hashine, Katsuyoshi"
324 results on '"Hashine, Katsuyoshi"'

1. Reproductive organ involvement in women undergoing radical cystectomy for urothelial bladder cancer: a nationwide multicenter study

Author

Kato, Minoru, Taoka, Rikiya, Miki, Jun, Saito, Ryoichi, Fukuokaya, Wataru, Matsui, Yoshiyuki, Yamamoto, Shoma, Matsue, Taisuke, Hatakeyama, Shingo, Kawahara, Takashi, Matsuda, Ayumu, Kawai, Taketo, Sazuka, Tomokazu, Sano, Takeshi, Urabe, Fumihiko, Kashima, Soki, Naito, Hirohito, Murakami, Yoji, Miyake, Makito, Daizumoto, Kei, Matsushita, Yuto, Hayashi, Takuji, Inokuchi, Junichi, Sugino, Yusuke, Shiga, Kenichiro, Yamaguchi, Noriya, Yamamoto, Shingo, Yasue, Keiji, Abe, Takashige, Nakanishi, Shotaro, Hashine, Katsuyoshi, Fujii, Masato, Nishihara, Kiyoaki, Matsumoto, Hiroaki, Tatarano, Shuichi, Wada, Koichiro, Sekito, Sho, Maruyama, Ryo, Nishiyama, Naotaka, Nishiyama, Hiroyuki, Kitamura, Hiroshi, and Uchida, Junji

Published
2024
Full Text
View/download PDF

5. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial

Author

Shiota, Masaki, Miyake, Hideaki, Takahashi, Masayuki, Oya, Mototsugu, Tsuchiya, Norihiko, Masumori, Naoya, Matsuyama, Hideyasu, Obara, Wataru, Shinohara, Nobuo, Fujimoto, Kiyohide, Nozawa, Masahiro, Ohba, Kojiro, Ohyama, Chikara, Hashine, Katsuyoshi, Akamatsu, Shusuke, Kamba, Tomomi, Mita, Koji, Gotoh, Momokazu, Tatarano, Shuichi, Fujisawa, Masato, Tomita, Yoshihiko, Mukai, Shoichiro, Ito, Keiichi, Tanegashima, Tokiyoshi, Tokunaga, Shoji, and Eto, Masatoshi

Published
2023
Full Text
View/download PDF

6. Ten-Year Outcomes of a Phase 3, Multicenter, Randomized Controlled Trial (SHIP0804) With 3-Month Neoadjuvant Androgen Deprivation Prior to 125I-Seed Transperineal Prostate Brachytherapy Followed by Nil Versus 9-Month Adjuvant Hormonal Therapy in Patients With Intermediate-Risk Prostate Cancer

Author

Momma, Tetsuo, Tsumura, Hideyasu, Fukagai, Takashi, Karasawa, Kumiko, Masui, Koji, Hashine, Katsuyoshi, Tanaka, Nobumichi, Katayama, Satoshi, Kusuhara, Yoshito, Eto, Masatoshi, Iinuma, Koji, Hayashi, Narihiko, Sugimoto, Mikio, Suzuki, Kazuhiro, Imamura, Ryoichi, Yonese, Junji, Fukuokaya, Wataru, Miki, Kenta, Aoki, Manabu, Takahashi, Hiroyuki, Saito, Shiro, Yorozu, Atsunori, Kikuchi, Takashi, Dokiya, Takushi, and Egawa, Shin

Published
2024
Full Text
View/download PDF

7. Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data

Author

Tomida, Ryotaro, Miyake, Makito, Minato, Ryoei, Sawada, Yuichiro, Matsumura, Masafumi, Iida, Kota, Hori, Shunta, Fukui, Shinji, Ohyama, Chikara, Miyake, Hideaki, Hongo, Fumiya, Taoka, Rikiya, Kobayashi, Takashi, Kojima, Takahiro, Matsui, Yoshiyuki, Nishiyama, Naotaka, Kitamura, Hiroshi, Nishiyama, Hiroyuki, Fujimoto, Kiyohide, and Hashine, Katsuyoshi

Published
2022
Full Text
View/download PDF

8. Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN

Author

Kato, Takuma, Hirama, Hiromi, Mitsuzuka, Koji, Maruyama, Satoru, Sasaki, Hiroshi, Saito, Toshihiro, Matsumoto, Ryuji, Sakamoto, Shinichi, Sakai, Yasuyuki, Fukuhara, Hiroshi, Naya, Yukio, Tsukino, Hiromasa, Hara, Isao, Ogawa, Osamu, Hashine, Katsuyoshi, Fumimasa, Fukuta, Yokomizo, Akira, Tohi, Yoichiro, Kakehi, Yoshiyuki, and Sugimoto, Mikio

Published
2022
Full Text
View/download PDF

9. A case of EBV-associated adrenal leiomyoma

Author

Takemoto, Takumasa, primary, Kiriyama, Ikuko, additional, Sugawara, Yoshifumi, additional, Abe, Chie, additional, Teramoto, Norihiro, additional, Hashine, Katsuyoshi, additional, Yoshida, Isao, additional, and Asagi, Akinori, additional

Published
2024
Full Text
View/download PDF

10. MP01-03 CURRENT TREATMENT PATTERNS AND OUTCOMES OF 109 PATIENTS WITH SEX CORD STROMAL TUMORS IN JAPAN: A MULTI-INSTITUTIONAL STUDY

Author

Abe, Takashige, primary, Miyai, Kosuke, additional, Tsuzuki, Toyonori, additional, Hashine, Katsuyoshi, additional, Yamashita, Shinichi, additional, Kawahara, Takashi, additional, Nishiya, Naotaka, additional, Kitamura, Hiroshi, additional, Nishiyama, Hiroyuki, additional, Miyata, Haruka, additional, Matusmoto, Ryuji, additional, Osawa, Takahiro, additional, Murai, Sachiyo, additional, and Shinohara, Nobuo, additional

Published
2024
Full Text
View/download PDF

11. Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study

Author

Tohi, Yoichiro, Kato, Takuma, Nakamura, Masaki, Matsumoto, Ryuji, Sasaki, Hiroshi, Mitsuzuka, Koji, Inokuchi, Junichi, Hashine, Katsuyoshi, Yokomizo, Akira, Naito, Hirohito, Hara, Isao, Kawamura, Norihiko, Inoue, Masaharu, Fukuhara, Hiroshi, Maruyama, Satoru, Sakamoto, Shinichi, Saito, Toshihiro, Egawa, Shin, Kakehi, Yoshiyuki, and Sugimoto, Mikio

Published
2022
Full Text
View/download PDF

12. Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN

Author

Hirama, Hiromi, Sugimoto, Mikio, Miyatake, Nobuyuki, Kato, Takuma, Venderbos, Lionne D. F., Remmers, Sebastiaan, Shiga, Kenichiro, Yokomizo, Akira, Mitsuzuka, Koji, Matsumoto, Ryuji, Osawa, Takahiro, Abe, Takashige, Sasaki, Hiroshi, Egawa, Shin, Ninomiya, Iku, Hashine, Katsuyoshi, Roobol, Monique J., and Kakehi, Yoshiyuki

Published
2021
Full Text
View/download PDF

13. Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS‐JAPAN).

Author

Kato, Takuma, Matsumoto, Ryuji, Yokomizo, Akira, Tohi, Yoichiro, Fukuhara, Hiroshi, Fujii, Yoichi, Mori, Keiichiro, Sato, Takuma, Inokuchi, Junichi, Hashine, Katsuyoshi, Sakamoto, Shinichi, Kinoshita, Hidefumi, Inoue, Koji, Tanikawa, Toshiki, Utsumi, Takanobu, Goto, Takayuki, Hara, Isao, Okuno, Hiroshi, Kakehi, Yoshiyuki, and Sugimoto, Mikio

Subjects
TUMOR antigens, PROSTATE cancer patients, MAGNETIC resonance imaging, WATCHFUL waiting, JAPANESE people
Abstract

Objective: To report the outcomes of repeat biopsies, metastasis and survival in the Prostate Cancer Research International: Active Surveillance (PRIAS)‐JAPAN study, a prospective observational study for Japanese patients, initiated in 2010. Patients and Methods: At the beginning, inclusion criteria were initially low‐risk patients, prostate‐specific antigen (PSA) density (PSAD) <0.2, and ≤2 positive biopsy cores. As from 2014, GS3+4 has also been allowed for patients aged 70 years and over. Since January 2021, the age limit for Gleason score (GS) 3 + 4 cases was removed, and eligibility criteria were expanded to PSA ≤20 ng/mL, PSAD <0.25 nd/mL/cc, unlimited number of positive GS 3 + 3 cores, and positive results for fewer than half of the total number of cores for GS 3 + 4 cases if magnetic resonance imaging fusion biopsy was performed at study enrolment or subsequent follow‐up. For patients eligible for active surveillance, PSA tests were performed every 3 months, rectal examination every 6 months, and biopsies at 1, 4, 7 and 10 years, followed by every 5 years thereafter. Patients with confirmed pathological reclassification were recommended for secondary treatments. Results: As of February 2024, 1302 patients were enrolled in AS; 1274 (98%) met the eligibility criteria. The median (interquartile range) age, PSA level, PSAD, and number of positive cores were 69 (64–73) years, 5.3 (4.5–6.6) ng/mL, 0.15 (0.12–0.17) ng/mL, and 1 (1–2), respectively. The clinical stage was T1c in 1089 patients (86%) and T2 in 185 (15%). The rates of acceptance by patients for the first, second, third and fourth re‐biopsies were 83%, 64%, 41% and 22%, respectively. The pathological reclassification rates for the first, second, third and fourth re‐biopsies were 29%, 30%, 35% and 25%, respectively. The 1‐, 5‐ and 10‐year persistence rates were 77%, 45% and 23%, respectively. Six patients developed metastasis, and one patient died from prostate cancer. Conclusion: Pathological reclassification was observed in approximately 30% of the patients during biopsy; however, biopsy acceptance rates decreased over time. Although metastasis occurred in six patients, only one death from prostate cancer was recorded. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Author

Park, Se Hoon, van der Heijden, Michiel S., Necchi, Andrea, Castellano, Daniel, Bamias, Aristotelis, Lee, Jae Lyun, De Giorgi, Ugo, Bögemann, Martin, Eigl, Bernhard J., Tsiatas, Marinos, Powles, Thomas, Novikov, Andrey, Skoneczna, Iwona, Mukherjee, Som D., Suarez, Cristina, Westgeest, Hans, Fradet, Yves, Flechon, Aude, Ou, Yen-Chuan, Park, Inkeun, Matveev, Vsevolod, Pérez-Valderrama, Begoña, Cheng, Susanna, Frank, Stephen, Gurney, Howard, Anido, Urbano, Hamzaj, Alketa, Retz, Margitta, Sridhar, Srikala, Scagliotti, Giorgio Vittorio, Voortman, Jens, Alekseev, Boris, Alyasova, Anna, Komyakov, Boris, Dumez, Herlinde, Pavic, Michel, Kimura, Go, Mizokami, Atsushi, Osanto, Susanne, Arranz, Jose Angel, Piersma, Djura, Shin, Sang Joon, Karyakin, Oleg, Delgado, Ignacio, Gonzalez, Jose Luis, Pang, See-Tong, Tran, Anna, Lipatov, Oleg, Su, Wen-Pin, Flaig, Thomas, Alva, Ajjai, Park Kyong, Hwa, Kopyltsov, Evgeny, Almagro, Elena, Domenech, Monserrat, Chang, Yen-Hwa, Sautois, Brieuc, Ravaux, Andre, Aravantinos, Gerasimos, Georgoulias, Vasileios, Mulder, Sasja, Kim, Yu Jung, Kater, Fabio, Chevreau, Christine, Tagawa, Scott, Zalewski, Pawel, Joly, Florence, Loriot, Yohann, Hatiboglu, Gencay, Gianni, Luca, Morelli, Franco, Tambaro, Rosa, Hashimoto, Yasuhiro, Nosov, Alexander, Font, Albert, Rodriguez-Vida, Alejo M., Jones, Robert, Vasudev, Naveen, Srinivas, Sandhya, Zhang, Jingsong, Gil, Thierry, Finch, Daygen, Grimm, Marc-Oliver, Su, Yu-Li, Chowdhury, Simon, Hocking, Christopher, Plas, Eugen, North, Scott, Jensen, Niels Viggo, Theodore, Christine, Imkamp, Florian, Peer, Avivit, Kobayashi, Takashi, Sakai, Hideki, Sassa, Naoto, Yoshimura, Kazuhiro, Aarts, Maureen, Ferreira Castro, Ana, Topuzov, Marlen, Rodriguez, Juan Francisco, Vazquez, Federico Jose, Tsai, Yu-Chieh, Crabb, Simon, Hussain, Syed, Bendell, Johanna, Gross-Goupil, Marine, Gwenaelle, Gravis, Berger, Raanan, Statsenko, Galina, Evans, Linda, Drakaki, Alexandra, Somer, Bradley, Davis, Ian, Lynam, James, Borges, Giuliano, Dettino, Aldo, Fay, André P., Martins, Graziella, Zucca, Luis Eduardo, Agerbaek, Mads, Kalofonos, Haralambos, Rosenbaum, Eli, Enokida, Hideki, Kikukawa, Hiroaki, Nishimura, Kazuo, Tamada, Satoshi, Uemura, Motohide, Lopez, Yamil, Gietema, Jourik, Slojewski, Marcin, Fernandes, Isabel, Smolin, Alexey, Mazhar, Danish, Kalebasty, Arash Rezazadeh, Carthon, Bradley, Loidl, Wolfgang, Franke, Fabio, Girotto, Gustavo, Alimohamed, Nimira, Macfarlane, Robyn, Pappot, Helle, Niegisch, Guenter, Mavroudis, Dimitrios, Sella, Avishay, Porta, Camillo, Ebara, Shin, Nakamura, Motonobu, Obara, Wataru, Okuno, Norihiko, Shinohara, Nobuo, Sugimoto, Mikio, Suzuki, Akitaka, Tokuda, Noriaki, Uemura, Hiroji, Yamaguchi, Akito, Ramirez, Francisco, Rozanowski, Pawel, Wiechno, Pawel, Keam, Bhumsuk, Kislov, Nikolay, Plaksin, Denis, Cicin, Irfan, Kumar, Satish, Galsky, Matthew D., Petrylak, Daniel P., Rosales, Joseph, Vaishampayan, Ulka, Culine, Stephane, Papandreou, Christos, Nara, Taketoshi, Erman, Mustafa, Kreiger, Laurence, Janoski, Juliana, Rosa, Diogo, Siqueira, Mariana, Canil, Christina, Sengelov, Lisa, Tourani, Jean-Marc, Arai, Gaku, Hashine, Katsuyoshi, Kawakita, Mutsushi, Nakaigawa, Noboru, Nomi, Hayahito, Shiina, Hiroaki, Suzuki, Hiroyoshi, Yonese, Junji, Kuri, Roberto, Macedo, Eleazar, Rivera, Samuel, Villalobos Prieto, Alberto, Polakiewicz-Gilowska, Anna, Zaucha, Renata, Lopes, Fabio, Ponomarev, Roman, Pomerantz, Mark, Shariat, Shahrokh, Luk, Cynthia, Lesniewski-Kmak, Krzysztof, van der Heijden, Michiel S, Galsky, Matthew D, Petrylak, Daniel P, Ogawa, Osamu, Lee, Jae-Lyun, Eigl, Bernhard J, Mukherjee, Som D, Suárez, Cristina, Fay, André P, Duran, Ignacio, Wildsmith, Sophie, He, Philip, Angra, Natasha, Gupta, Ashok K, Levin, Wendy, and Bellmunt, Joaquim

Published
2020
Full Text
View/download PDF

15. Salvage Radiotherapy Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401)†

Author

Yokomizo, Akira, Wakabayashi, Masashi, Satoh, Takefumi, Hashine, Katsuyoshi, Inoue, Takahiro, Fujimoto, Kiyohide, Egawa, Shin, Habuchi, Tomonori, Kawashima, Kiyotaka, Ishizuka, Osamu, Shinohara, Nobuo, Sugimoto, Mikio, Yoshino, Yasushi, Nihei, Keiji, Fukuda, Haruhiko, Tobisu, Ken-ichi, Kakehi, Yoshiyuki, and Naito, Seiji

Published
2020
Full Text
View/download PDF

16. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Author

Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Wan Ng, Siobhan Su, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Joly, Florence, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Schwentner, Christina A, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Révész, Janos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Sarid, David, Scagliotti, Giorgio Vittorio, Bracarda, Sergio, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Vazquez Cortés, Leticia, Lorena Urzua Flores, Claudia, Blaisse, Reinoud J.B., Erdkamp, Fransiscus L.G., Aarts, Maureen J.B., Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Fomkin, Roman, Gajate Borau, Pablo, Grande, Enrique, Delgado Mignorance, Juan Ignacio, Su, Yu-Li, Li, Jian-Ri, Lin, Chien-Liang, Lin, Chia-Chi, Yeh, Su-Peng, Erman, Mustafa, Urun, Yuksel, Golovko, Yuriy, Bondarenko, Igor, Sinielnikov, Ivan, Crabb, Simon J., Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Flaig, Thomas W., Pan, Chong Xian, Schwarz, James K., Cultrera, Jennifer Lyn, Acs, Peter Istvan, Hainsworth, John D., Herms, Benjamin T., Lawler, William Eyre, Lowe, Thomas Eugene, Petrylak, Daniel P, de Wit, Ronald, Chi, Kim N, Drakaki, Alexandra, Sternberg, Cora N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed A, Fléchon, Aude, Bamias, Aristotelis, Yu, Evan Y, van der Heijden, Michiel S, Matsubara, Nobuaki, Alekseev, Boris, Necchi, Andrea, Géczi, Lajos, Ou, Yen-Chuan, Coskun, Hasan Senol, Su, Wen-Pin, Bedke, Jens, Gakis, Georgios, Percent, Ivor J, Lee, Jae-Lyun, Tucci, Marcello, Semenov, Andrey, Laestadius, Fredrik, Peer, Avivit, Tortora, Giampaolo, Safina, Sufia, Garcia del Muro, Xavier, Rodriguez-Vida, Alejo, Cicin, Irfan, Harputluoglu, Hakan, Tagawa, Scott T, Vaishampayan, Ulka, Aragon-Ching, Jeanny B, Hamid, Oday, Liepa, Astra M, Wijayawardana, Sameera, Russo, Francesca, Walgren, Richard A, Zimmermann, Annamaria H, Hozak, Rebecca R, Bell-McGuinn, Katherine M, and Powles, Thomas

Published
2020
Full Text
View/download PDF

17. The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study

Author

Tohi, Yoichiro, Kato, Takuma, Matsumoto, Ryuji, Shinohara, Nobuo, Shiga, Kenichiro, Yokomizo, Akira, Nakamura, Masaki, Kume, Haruki, Mitsuzuka, Koji, Sasaki, Hiroshi, Egawa, Shin, Matsumura, Masafumi, Hashine, Katsuyoshi, Inokuchi, Junichi, Eto, Masatoshi, Baba, Haruki, Ichikawa, Tomohiko, Kinoshita, Hidefumi, Matsuda, Tadashi, Kakehi, Yoshiyuki, and Sugimoto, Mikio

Published
2020
Full Text
View/download PDF

20. Validation study on the 2 mm diameter cutoff in lymph node‐positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real‐world data analysis from a Japanese cohort.

Author

Kato, Masashi, Shiota, Masaki, Kimura, Takahiro, Hanazawa, Ryoichi, Hirakawa, Akihiro, Takamatsu, Dai, Tashiro, Kojiro, Matsui, Yoshiyuki, Hashine, Katsuyoshi, Saito, Ryoichi, Yokomizo, Akira, Yamamoto, Yoshiyuki, Narita, Shintaro, Hashimoto, Kohei, Matsumoto, Hiroaki, Akamatsu, Shusuke, Nishiyama, Naotaka, Eto, Masatoshi, Kitamura, Hiroshi, and Tsuzuki, Toyonori

Subjects
RADICAL prostatectomy, MICROMETASTASIS, PROSTATE cancer, CANCER patients, PROSTATE cancer patients, LYMPHATIC metastasis, DATA analysis
Abstract

Objectives: The American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) 8th edition has proposed micrometastasis as a lymph node metastasis (LN+) of diameter ≤2 mm in prostate cancer. However, supporting evidence has not described. We evaluated LN+ patients' survival after radical prostatectomy (RP) based on the LN maximum tumor diameter (MTD). Methods: Data from 561 LN+ patients after RP and pelvic LN dissection (PLND) treated between 2006 and 2019 at 33 institutions were retrospectively investigated. Patients were stratified by a LN+ MTD cutoff of 2 mm. Outcomes included castration resistance‐free survival (CRFS), metastasis‐free survival (MFS), cancer‐specific survival (CSS), and overall survival (OS). Results: In total, 282 patients were divided into two groups (LN+ MTD >2 mm [n = 206] and ≤2 mm [n = 76]). Patients of LN+ status >2 mm exhibited significantly decreased CRFS and MFS, and poorer CSS and OS. No patients developed CRPC in the LN+ status ≤2 mm group when the PLND number was ≥14. Multivariate analysis showed the number of LN removed, RP Gleason pattern 5, and MTD in LN+ significantly predicted CRFS. Conclusions: Patients of LN+ status ≤2 mm showed better prognoses after RP. In all the patients in the ≤2‐mm group, the progression to CRPC could be prevented with appropriate interventions, particularly when PLND is performed accurately. Our findings support the utility of the pN substaging proposed by the AJCC/UICC 8th edition; this will facilitate precision medicine for patients with advanced prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Correction to: The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study

Author

Tohi, Yoichiro, Kato, Takuma, Matsumoto, Ryuji, Shinohara, Nobuo, Shiga, Kenichiro, Yokomizo, Akira, Nakamura, Masaki, Kume, Haruki, Mitsuzuka, Koji, Sasaki, Hiroshi, Egawa, Shin, Matsumura, Masafumi, Hashine, Katsuyoshi, Inokuchi, Junichi, Eto, Masatoshi, Baba, Haruki, Ichikawa, Tomohiko, Kinoshita, Hidefumi, Matsuda, Tadashi, Kakehi, Yoshiyuki, and Sugimoto, Mikio

Published
2022
Full Text
View/download PDF

24. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Author

Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Ng, Siobhan Su Wan, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Chi, Kim Nguyen, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Laestadius, Fredrik, Joly, Florence, Flechon, Aude, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Gakis, Georgios, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Bamias, Aristotelis, Révész, Janos, Geczi, Lajos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Peer, Avivit, Sarid, David, Scagliotti, Giorgio Vittorio, Sternberg, Cora N, Tortora, Giampaolo, Bracarda, Sergio, Necchi, Andrea, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Matsubara, Nobuaki, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Jae-Lyun, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Cortés, Leticia Vazquez, Flores, Claudia Lorena Urzua, Blaisse, Reinoud J B, van der Heijden, Michiel S, de Wit, Ronald, Erdkamp, Fransiscus L G, Aarts, Maureen J B, Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Safina, Sufia Z, Alekseev, Boris, Semenov, Andrey, Fomkin, Roman, Pulido, Enrique Grande, Del Muro, F Xavier García, Mignorance, Juan Ignacio Delgado, Gauna, Daniel Castellano, Rodríguez-Vida, Alejo, Su, Yu-Li, Ou, Yen-Chuan, Lin, Chien-Liang, Su, Wen-Pin, Lin, Chia-Chi, Yeh, Su-Peng, Çiçin, Irfan, Harputluoglu, Hakan, Erman, Mustafa, Coskun, Hasan Senol, Urun, Yuksel, Golovko, Yurii, Bondarenko, Igor, Sinielnikov, Ivan, Powles, Thomas, Crabb, Simon, Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Drakaki, Alexandra, Flaig, Thomas, Pan, Chong Xian, Petrylak, Daniel, Schwarz, James, Percent, Ivor, Cultrera, Jennifer, Hainsworth, John, Herms, Benjamin, Lawler, William, Lowe, Thomas, Tagawa, Scott, Aragon-Ching, Jeanny, Vaishampayan, Ulka, Petrylak, Daniel P, Chi, Kim N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed, Fléchon, Aude, Yu, Evan Y, Géczi, Lajos, Hegemann, Miriam, Percent, Ivor J, Tucci, Marcello, Safina, Sufia, del Muro, Xavier Garcia, Rodriguez-Vida, Alejo, Cicin, Irfan, Widau, Ryan C, Liepa, Astra M, Walgren, Richard A, Hamid, Oday, Zimmermann, Annamaria H, and Bell-McGuinn, Katherine M

Published
2017
Full Text
View/download PDF

27. Radical prostatectomy trends between 2010 and 2020 in Ehime, Japan, identified using data from the Medical Investigation Cancer Network (MICAN) study

Author

Hashine, Katsuyoshi, primary, Yamashita, Natsumi, additional, Tachou, Takatoshi, additional, Kan, Masaharu, additional, Yanagaki, Takahiro, additional, Oka, Akihiro, additional, Takeda, Hajime, additional, Shirato, Akitomi, additional, Watanabe, Uichi, additional, Miura, Noriyoshi, additional, and Saika, Takashi, additional

Published
2023
Full Text
View/download PDF

28. Oncological outcomes with wide resection in robot-assisted radical prostatectomy as primary treatment for very high-risk prostate cancer.

Author

Miura, Noriyoshi, primary, Hashine, Katsuyoshi, additional, Watanabe, Ryuta, additional, Noda, Terutaka, additional, Nishimura, Kenichi, additional, Fukumoto, Tetsuya, additional, Miyauchi, Yuki, additional, Kikugawa, Tadahiko, additional, Tacho, Takatoshi, additional, Yanagaki, Takahiro, additional, Oka, Akihiro, additional, Takeda, Hajime, additional, Watanabe, Yuichi, additional, Ninomiya, Iku, additional, Shirato, Akitomi, additional, and Saika, Takashi, additional

Published
2023
Full Text
View/download PDF

30. Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP‐RCC study.

Author

Blas, Leandro, Shiota, Masaki, Miyake, Hideaki, Takahashi, Masayuki, Oya, Mototsugu, Tsuchiya, Norihiko, Masumori, Naoya, Matsuyama, Hideyasu, Obara, Wataru, Shinohara, Nobuo, Fujimoto, Kiyohide, Nozawa, Masahiro, Ohba, Kojiro, Ohyama, Chikara, Hashine, Katsuyoshi, Akamatsu, Shusuke, Kamba, Tomomi, Mita, Koji, Gotoh, Momokazu, and Tatarano, Shuichi

Subjects
NIVOLUMAB, KARNOFSKY Performance Status, PROGNOSIS, JAPANESE people, PROGRESSION-free survival, RENAL cell carcinoma
Abstract

Background: This study is part of the SNPs in Nivolumab PD‐1 inhibitor for RCC (SNiP‐RCC). Here we aimed to reveal clinical factors for tumor response, progression, and survival in nivolumab for advanced clear cell renal cell carcinoma (RCC) in Japanese patients. Methods: We included patients from 23 institutions in Japan. We evaluated the objective response, radiographic progression‐free survival (PFS), overall survival (OS), and treatment‐related grade ≥ 3 (serious adverse events [SAEs]). Results: We included 222 patients. The median age was 69 years (interquartile range 62–74 years), and 71% of the patients were male. Pancreas metastasis, lung metastases, prior cytokine therapy, and SAEs, were associated with objective response. The median PFS was 18 months. Liver metastases (hazard ratio [HR], 1.61), age ≥ 75 (HR, 0.48), previous resection of primary sites (HR, 0.47), and SAEs (HR, 0.47) were independent prognostic factors for PFS. Karnofsky Performance Status <70 (HR, 2.90), high platelets (HR, 4.48), previous resection of primary sites (HR, 0.23), and pathological grade (HR, 0.19 for grade 2 and HR, 0.12 for grade 3) were independent prognostic factors for OS. SAEs were reported in 45 (20.3%) cases. In the group of patients with prior nephrectomy, SAEs were associated with objective response, PFS, and OS. Conclusion: The SNiP‐RCC study identified clinical parameters correlated with treatment outcomes in Japanese patients with priorly treated advanced clear cell RCC undergoing nivolumab monotherapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis

Author

KAMIJIMA, TAIKI, primary, YAEGASHI, HIROSHI, additional, MIZOKAMI, ATSUSHI, additional, NAKAJIMA, KENICHI, additional, MATSUYAMA, HIDEYASU, additional, ICHIKAWA, TOMOHIKO, additional, NISHIMOTO, KOSHIRO, additional, TAKAHASHI, SATORU, additional, SHIINA, HIROAKI, additional, HORIKOSHI, HIROYUKI, additional, HASHINE, KATSUYOSHI, additional, SUGIYAMA, YUTAKA, additional, MIYAO, TAKESHI, additional, KAMIYAMA, MANABU, additional, HARADA, KENICHI, additional, ITO, AKITO, additional, and ENOKIDA, HIDEKI, additional

Published
2022
Full Text
View/download PDF

34. Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice

Author

MIZOKAMI, ATSUSHI, primary, NISHIMOTO, KOSHIRO, additional, MATSUYAMA, HIDEYASU, additional, ICHIKAWA, TOMOHIKO, additional, TAKAHASHI, SATORU, additional, SHIINA, HIROAKI, additional, HASHINE, KATSUYOSHI, additional, SUGIYAMA, YUTAKA, additional, KAMIYAMA, MANABU, additional, ENOKIDA, HIDEKI, additional, and NAKAJIMA, KENICHI, additional

Published
2022
Full Text
View/download PDF

35. Validation of the STAR-CAP clinical prognostic system for predicting biochemical recurrence after radical prostatectomy in a Japanese cohort.

Author

Miura, Noriyoshi, primary, Miyauchi, Yuki, additional, Kikugawa, Tadahiko, additional, Oka, Akihiro, additional, Sawada, Yuichiro, additional, Tomida, Ryotaro, additional, Matsumura, Masafumi, additional, Hashine, Katsuyoshi, additional, Yanagihara, Yutaka, additional, Ninomiya, Iku, additional, Kan, Masaharu, additional, Yano, Akira, additional, Tacho, Takatoshi, additional, Yanagaki, Takahiro, additional, Takeda, Hajime, additional, Watanabe, Yuichi, additional, and Saika, Takashi, additional

Published
2022
Full Text
View/download PDF

39. Predictive factors for the effectiveness of novel androgen receptor axis‐targeted agents in patients with metastatic prostate cancer.

Author

Koshiro, Nishimoto, Nakajima, Kenichi, Oyama, Masafumi, Kaneko, Go, Takahashi, Satoru, Matsuyama, Hideyasu, Shiina, Hiroaki, Ichikawa, Tomohiko, Horikoshi, Hiroyuki, Hashine, Katsuyoshi, Sugiyama, Yutaka, Miyao, Takeshi, Kamiyama, Manabu, Harada, Kenichi, Ito, Akito, and Mizokami, Atsushi

Subjects
ANDROGEN receptors, PROSTATE cancer patients, CASTRATION-resistant prostate cancer, BONE metastasis, RADIONUCLIDE imaging
Abstract

Objective: Novel androgen receptor axis‐targeted agents (ARATAs) have been developed for mCRPC and improved overall survival (OS). Here, we aimed to find predictors who will receive the greatest benefits from ARATAs. Methods: We previously performed a multicenter study to identify prognostic factors for metastatic hormone‐sensitive prostate cancer (mHSPC, n = 148) and mCRPC (n = 99), and showed that the bone scan index (BSI) was one of the significant prognostic factors for 3‐year OS (PROSTAT‐BSI study). mHSPC progressed to mCRPC (n = 101), for which 69 patients were treated with (n = 39) or without ARATAs (n = 30, prior to the approval of ARATAs). The 69 patients were divided into two groups according to patient factors, and these cohorts were further divided into two subgroups by usage of ARATAs. OS was compared between subgroups in each group. Results: The predictors were age (<71.4 years), serum levels of C‐reactive protein (≥0.16 ng/ml) and alkaline phosphatase (≥548 U/L), time to PSA progression after ADT (<8.9 months), the lowest PSA level (≥1 ng/ml) after ADT, and the rate of PSA decline 3 months after ADT (<0.987), whereas hemoglobin levels, PSA before ADT, Gleason scores, existence of visceral metastases, and BSI were not. Conclusions: The present study identified predictors for the effectiveness of ARATAs. The number of bone metastases (≒BSI), existence of visceral metastases, and Gleason scores, which were identified as high‐risk factors in the LATITUDE study and disease volume in CHAARTED criteria, did not appear to be useful for predicting effectiveness from ARATAs. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan

Author

Nishimura, Kazuo, Nonomura, Norio, Hashine, Katsuyoshi, Kanayama, Hiro-omi, Ozono, Seiichiro, Miura, Takeshi, Miki, Tsuneharu, Kakehi, Yoshiyuki, Arai, Yoichi, Ogawa, Osamu, Fujita, Ryuji, Nonomura, Katsuya, Mizokami, Atsushi, Hoshi, Senji, and Akaza, Hideyuki

Published
2013
Full Text
View/download PDF

42. Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study

Author

Tohi, Yoichiro, primary, Kato, Takuma, additional, Nakamura, Masaki, additional, Matsumoto, Ryuji, additional, Sasaki, Hiroshi, additional, Mitsuzuka, Koji, additional, Inokuchi, Junichi, additional, Hashine, Katsuyoshi, additional, Yokomizo, Akira, additional, Naito, Hirohito, additional, Hara, Isao, additional, Kawamura, Norihiko, additional, Inoue, Masaharu, additional, Fukuhara, Hiroshi, additional, Maruyama, Satoru, additional, Sakamoto, Shinichi, additional, Saito, Toshihiro, additional, Egawa, Shin, additional, Kakehi, Yoshiyuki, additional, and Sugimoto, Mikio, additional

Published
2021
Full Text
View/download PDF

49. Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN

Author

Kato, Takuma, primary, Hirama, Hiromi, additional, Mitsuzuka, Koji, additional, Maruyama, Satoru, additional, Sasaki, Hiroshi, additional, Saito, Toshihiro, additional, Matsumoto, Ryuji, additional, Sakamoto, Shinichi, additional, Sakai, Yasuyuki, additional, Fukuhara, Hiroshi, additional, Naya, Yukio, additional, Tsukino, Hiromasa, additional, Hara, Isao, additional, Ogawa, Osamu, additional, Hashine, Katsuyoshi, additional, Fumimasa, Fukuta, additional, Yokomizo, Akira, additional, Tohi, Yoichiro, additional, Kakehi, Yoshiyuki, additional, and Sugimoto, Mikio, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results